Stryker

Q2 FY2026 EarningsQ2 FY26 results slightly beat consensus on the top line with revenue of $6.59B vs. $6.58B expected, while adjusted EPS of $3.69 significantly outperformed the $3.49 estimate (+5.8%). The beat was driven by a robust gross margin of 66.0% (adjusted), which exceeded expectations by 0.91pct, largely due to a reversal of 2025 tariffs. MedSurg and Neurotechnology led organic growth, despite a $158M one-time tariff benefit boosting overall profitability. Operating cash flow for the first half of FY26 reached $1.84B, surpassing the full Q2 consensus of $1.06B.